Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg

NCT02952937 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLA5PR GLARS-NF3 tablet 300mg
DRUG: GLA5PR GLARS-NF1 tablet 300mg

Sponsor

GL Pharm Tech Corporation